<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585829</url>
  </required_header>
  <id_info>
    <org_study_id>100</org_study_id>
    <nct_id>NCT03585829</nct_id>
  </id_info>
  <brief_title>Ramadan Fasting in Patients With Corticotrope Deficiency Treated Either by Hydrocortisone or by Prednisolone</brief_title>
  <official_title>Comparison of the Risk of Complications and the Quality of Life During Ramadan Fasting in Patients With Corticotrope Deficiency Treated Either by Hydrocortisone or by Prednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Tunis El Manar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Tunis El Manar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selected patients will be randomised to either hydrocortisone or prednisolone. Each treatment&#xD;
      period is of 14 days. Abnormal clinical symptoms, blood glucose and quality of life will be&#xD;
      monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Selection of the patients who meet the inclusion and non inclusion criteria.&#xD;
&#xD;
        -  Detailed explanations about the study to the patients.&#xD;
&#xD;
        -  Signature of the informed consent by the patients.&#xD;
&#xD;
        -  Randomisation of the patients by drawing lots into two groups; group AB who will receive&#xD;
           treatment A during 14 days (period 1) then treatment B during 14 days (period 2) and&#xD;
           group BA who will receive treatment B during 14 days (period 1) then treatment A during&#xD;
           14 days (period 2).&#xD;
&#xD;
        -  Each patient will receive a daily follow-up sheet, a quality of life questionnaire, a&#xD;
           glucometer with test strips and the treatment in different bottles for each period of&#xD;
           the study.&#xD;
&#xD;
        -  The daily follow-up sheet concerns habits during Ramadan (eating, sleeping), the&#xD;
           occurrence of complications and blood glucose monitoring. Daily blood glucose monitoring&#xD;
           is requested at midday, before dinner and if a malaise occurs. A detailed questionnaire&#xD;
           on abnormal symptoms that might occur during fasting have to be fulfilled for each&#xD;
           malaise.&#xD;
&#xD;
        -  Quality of life will be evaluated using AddiQol questionnaire translated in Tunisian&#xD;
           dialect. Patients have to complete the questionnaire before the fasting month and at the&#xD;
           end of each period of treatment.&#xD;
&#xD;
        -  Treatment is presented in the form of capsules with the same colour and size. Patients&#xD;
           have to take one capsule at dinner and one capsule at pre-dawn meal. Patients will&#xD;
           receive either hydrocortisone 15mg at pre-dawn meal and 5mg at dinner (sunset)&#xD;
           (treatment A) or prednisolone 5mg at pre-dawn meal and a placebo (starch) at dinner&#xD;
           (treatment B).&#xD;
&#xD;
        -  During the study, patients will be in regular phone contact with a responsible of the&#xD;
           study for any information or problem.&#xD;
&#xD;
        -  At the end of the study, the completed follow-up sheets and questionnaires will be&#xD;
           picked up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>crossover clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>the treatment has been put in capsules with the same size and color</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of complications</measure>
    <time_frame>during the fourteen days treatment period</time_frame>
    <description>fatigue, asthenia, symptoms of hypoglycemia, symptoms of dehydration, hypoglycemia on blood glucose monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>score of quality of life</measure>
    <time_frame>during the fourteen days treatment period</time_frame>
    <description>using a questionnaire (AddiQol)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Corticotropin Deficiency</condition>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>at a substitutive dosage</description>
    <arm_group_label>hydrocortisone</arm_group_label>
    <other_name>Cortef*</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>at a substitutive dosage</description>
    <arm_group_label>prednisolone</arm_group_label>
    <other_name>Vitapred*</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known corticotrope deficiency treated by 20mg hydrocortisone per day.&#xD;
&#xD;
          -  Age: 18-70 years&#xD;
&#xD;
          -  patients who are willing to fast Ramadan 2018 and who voluntary accept to participate&#xD;
             in the study.&#xD;
&#xD;
        Non inclusion criteria:&#xD;
&#xD;
        Patients with either diabetes mellitus, hypertension, diabetes insipidus, severe organ&#xD;
        damage (renal, cardiac, pulmonary, hepatic), neoplasia, psychiatric disease, epilepsy or&#xD;
        pregnant or breast-feeding women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The occurrence of any of the non inclusion criteria during the study. The occurrence of a&#xD;
        severe malaise.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedia Slimane, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Tunis El Manar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Tunis El Manar</name>
      <address>
        <city>Tunis</city>
        <zip>1068</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Tunis El Manar</investigator_affiliation>
    <investigator_full_name>Melika Chihaoui</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>treatment</keyword>
  <keyword>quality of life</keyword>
  <keyword>hypoglycemia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

